First biologic treatments for moderate-to-severe ulcerative colitis
Part of Digestive system clinical trials.
This study compares four newer biologic medications (infliximab, filgotinib, vedolizumab, and ustekinumab) to find which works best as a first biologic treatment for ulcerative colitis that hasn't responded well to standard drugs. It aims to help doctors choose the right biologic for each patient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ulcerative colitis for at least 3 months
- Your disease is moderate to severe and has not responded well to standard treatments (5-ASA, steroids, or immunosuppressants)
- You are between 18 and 65 years old
- You have never received biologic drugs before (such as anti-TNF agents, vedolizumab, or JAK inhibitors)
- You are covered by the French healthcare system and speak French
- Women of childbearing age must use active contraception and have a negative pregnancy test
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two first-line biologic drugs for moderate to severe ulcerative colitis to see which works better and why. The goal is to help find the best biologic treatment for each patient.
This trial is comparing two biologic medicines, ustekinumab (Stelara) and infliximab (Remicade), to see which one works better for moderate to severe ulcerative colitis. It is for people who have never taken a biologic before.
This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.
This study looks at how well different biologic medications work for people with moderate to severe ulcerative colitis or Crohn's disease after one year of treatment. The goal is to see which treatment helps the gut heal best.
This trial compares three types of medications (vedolizumab, ustekinumab, and JAK inhibitors) in people with ulcerative colitis who have already tried an anti-TNF drug but still have active disease. The goal is to see which treatment works best as a second option.
This study compares an existing UC medication (infliximab) with a newer one (ustekinumab) and a combination of both. The goal is to see which works best for moderate to severe UC when other treatments have failed.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.